Small Cell Lung Cancer

Restricted access

Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.

  • 1

    Oberg K, Hellman P, Kwekkeboom D, Jelic S. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v220222.

    • Search Google Scholar
    • Export Citation
  • 2

    Govindan R, Page N, Morgensztern D. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:45394544.

    • Search Google Scholar
    • Export Citation
  • 3

    Navada S, Lai P, Schwartz A, Kalemkerian G. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 7082.

    • Search Google Scholar
    • Export Citation
  • 4

    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:1029.

  • 5

    Murray N, Turrisi AT III. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 2006;1:270278.

  • 6

    Hann CL, Rudin CM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park) 2008;22:14861492.

    • Search Google Scholar
    • Export Citation
  • 7

    Johnson BE, Janne PA. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am 2004;18:309322.

    • Search Google Scholar
    • Export Citation
  • 8

    Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010;35:202215.

    • Search Google Scholar
    • Export Citation
  • 9

    Videtic GM, Stitt LW, Dar AR. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21:15441549.

    • Search Google Scholar
    • Export Citation
  • 10

    Zakowski MF. Pathology of small cell carcinoma of the lung. Semin Oncol 2003;30:38.

  • 11

    Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004;22:27302739.

  • 12

    Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. Cancer 1997;79:17291736.

  • 13

    Remick SC, Ruckdeschel JC. Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome. Med Pediatr Oncol 1992;20:8999.

    • Search Google Scholar
    • Export Citation
  • 14

    Johnson BE, Whang-Peng J, Naylor SL. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J Natl Cancer Inst 1989;81:12231228.

    • Search Google Scholar
    • Export Citation
  • 15

    Guinee DG Jr, Fishback NF, Koss MN. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 1994;102:406414.

    • Search Google Scholar
    • Export Citation
  • 16

    Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol 2010;21(Suppl 7):vii6571.

  • 17

    Gustafsson BI, Kidd M, Chan A. Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:521.

  • 18

    Renshaw AA, Haja J, Lozano RL, Wilbur DC. Distinguishing carcinoid tumor from small cell carcinoma of the lung: correlating cytologic features and performance in the College of American Pathologists Non-Gynecologic Cytology Program. Arch Pathol Lab Med 2005;129:614618.

    • Search Google Scholar
    • Export Citation
  • 19

    Aberle DR, Adams AM, Berg CD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395409.

  • 20

    Cuffe S, Moua T, Summerfield R. Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. J Thorac Oncol 2011;6:818822.

    • Search Google Scholar
    • Export Citation
  • 21

    Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw 2006;4:631638.

  • 22

    Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer 2011;10:33.

    • Search Google Scholar
    • Export Citation
  • 23

    Marchioli CC, Graziano SL. Paraneoplastic syndromes associated with small cell lung cancer. Chest Surg Clin N Am 1997;7:6580.

  • 24

    Titulaer MJ, Wirtz PW, Willems LN. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008;26:42764281.

    • Search Google Scholar
    • Export Citation
  • 25

    Meriney SD, Hulsizer SC, Lennon VA, Grinnell AD. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol 1996;40:739749.

    • Search Google Scholar
    • Export Citation
  • 26

    Graus F, Keime-Guibert F, Rene R. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:11381148.

  • 27

    Delisle L, Boyer MJ, Warr D. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med 1993;153:746752.

    • Search Google Scholar
    • Export Citation
  • 28

    Johnson BE, Chute JP, Rushin J. A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J Respir Crit Care Med 1997;156:16691678.

    • Search Google Scholar
    • Export Citation
  • 29

    Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist 2012;17:756765.

  • 30

    Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc 2010;85:838854.

  • 31

    Schrier RW, Gross P, Gheorghiade M. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:20992112.

    • Search Google Scholar
    • Export Citation
  • 32

    Verbalis JG, Zeltser D, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf) 2008;69:159168.

    • Search Google Scholar
    • Export Citation
  • 33

    Micke P, Faldum A, Metz T. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? Lung Cancer 2002;37:271276.

    • Search Google Scholar
    • Export Citation
  • 34

    Kalemkerian GP. Staging and imaging of small cell lung cancer. Cancer Imaging 2011;11:253258.

  • 35

    Shepherd FA, Crowley J, Van Houtte P. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:10671077.

    • Search Google Scholar
    • Export Citation
  • 36

    Ignatius Ou SH, Zell JA. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. J Thorac Oncol 2009;4:300310.

    • Search Google Scholar
    • Export Citation
  • 37

    Vallieres E, Shepherd FA, Crowley J. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:10491059.

    • Search Google Scholar
    • Export Citation
  • 38

    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.

  • 39

    Goldstraw P, Crowley J, Chansky K. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706714.

    • Search Google Scholar
    • Export Citation
  • 40

    Podoloff DA, Ball DW, Ben-Josef E. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 2009;7(Suppl 2):S126.

    • Search Google Scholar
    • Export Citation
  • 41

    Bradley JD, Dehdashti F, Mintun MA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004;22:32483254.

    • Search Google Scholar
    • Export Citation
  • 42

    Kut V, Spies W, Spies S. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol 2007;30:4550.

    • Search Google Scholar
    • Export Citation
  • 43

    Azad A, Chionh F, Scott AM. High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol 2010;12:443451.

    • Search Google Scholar
    • Export Citation
  • 44

    Fischer BM, Mortensen J, Langer SW. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007;18:338345.

    • Search Google Scholar
    • Export Citation
  • 45

    Brink I, Schumacher T, Mix M. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:16141620.

    • Search Google Scholar
    • Export Citation
  • 46

    Kamel EM, Zwahlen D, Wyss MT. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003;44:19111917.

    • Search Google Scholar
    • Export Citation
  • 47

    Vinjamuri M, Craig M, Campbell-Fontaine A. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer 2008;9:3034.

    • Search Google Scholar
    • Export Citation
  • 48

    Foster NR, Mandrekar SJ, Schild SE. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer 2009;115:27212731.

    • Search Google Scholar
    • Export Citation
  • 49

    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:15631574.

    • Search Google Scholar
    • Export Citation
  • 50

    Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 2000;28:173185.

  • 51

    Postmus PE, Haaxma-Reiche H, Gregor A. Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol 1998;46:2932.

    • Search Google Scholar
    • Export Citation
  • 52

    Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004;49:119133.

  • 53

    Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379392.

  • 54

    Johnson BE. Management of small cell lung cancer. Clin Chest Med 2002;23:225239.

  • 55

    Evans WK, Shepherd FA, Feld R. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:14711477.

  • 56

    Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:13851396.

  • 57

    Sundstrom S, Bremnes RM, Kaasa S. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol 2002;20:46654672.

    • Search Google Scholar
    • Export Citation
  • 58

    Bishop JF, Raghavan D, Stuart-Harris R. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 1987;5:15741578.

    • Search Google Scholar
    • Export Citation
  • 59

    Skarlos DV, Samantas E, Kosmidis P. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5:601607.

    • Search Google Scholar
    • Export Citation
  • 60

    Okamoto H, Watanabe K, Kunikane H. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007;97:162169.

    • Search Google Scholar
    • Export Citation
  • 61

    Rossi A, Di Maio M, Chiodini P. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30:16921698.

    • Search Google Scholar
    • Export Citation
  • 62

    Noda K, Nishiwaki Y, Kawahara M. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:8591.

    • Search Google Scholar
    • Export Citation
  • 63

    Lara PN Jr, Natale R, Crowley J. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:25302535.

    • Search Google Scholar
    • Export Citation
  • 64

    Hanna N, Bunn PA Jr, Langer C. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer 10.1200/JCO.2005.04.8595. J Clin Oncol 2006;24:20382043.

    • Search Google Scholar
    • Export Citation
  • 65

    Schmittel A, Fischer von Weikersthal L, Sebastian M. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006;17:663667.

    • Search Google Scholar
    • Export Citation
  • 66

    Hermes A, Bergman B, Bremnes R. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008;26:42614267.

    • Search Google Scholar
    • Export Citation
  • 67

    Lima JP, dos Santos LV, Sasse EC. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol 2010;5:19861993.

    • Search Google Scholar
    • Export Citation
  • 68

    Chute JP, Chen T, Feigal E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:17941801.

    • Search Google Scholar
    • Export Citation
  • 69

    Loehrer PJ Sr, Ansari R, Gonin R. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995;13:25942599.

    • Search Google Scholar
    • Export Citation
  • 70

    Pujol JL, Daures JP, Riviere A. Etoposide plus cisplatin with or without the combination of 4’-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001;93:300308.

    • Search Google Scholar
    • Export Citation
  • 71

    Miyamoto H, Nakabayashi T, Isobe H. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 1992;49:431435.

    • Search Google Scholar
    • Export Citation
  • 72

    Niell HB, Herndon JE II, Miller AA. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732. J Clin Oncol 2005;23:37523759.

    • Search Google Scholar
    • Export Citation
  • 73

    Schiller JH, Adak S, Cella D. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:21142122.

    • Search Google Scholar
    • Export Citation
  • 74

    Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:17271733.

    • Search Google Scholar
    • Export Citation
  • 75

    Fukuoka M, Furuse K, Saijo N. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855861.

    • Search Google Scholar
    • Export Citation
  • 76

    Roth BJ, Johnson DH, Einhorn LH. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282291.

    • Search Google Scholar
    • Export Citation
  • 77

    Miles DW, Earl HM, Souhami RL. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol 1991;9:280285.

    • Search Google Scholar
    • Export Citation
  • 78

    Murray N, Gelmon K, Shah A. Potential for long-term survival in extensive stage small-cell lung cancer (ESCLC) with CODE chemotherapy and radiotherapy [abstract]. Lung Cancer 1994;11(Suppl 1):99. Abstract 377.

    • Search Google Scholar
    • Export Citation
  • 79

    Sculier JP, Paesmans M, Bureau G. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993;11:18581865.

    • Search Google Scholar
    • Export Citation
  • 80

    Souhami RL, Rudd R, Ruiz de Elvira MC. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994;12:18061813.

    • Search Google Scholar
    • Export Citation
  • 81

    Fukuoka M, Masuda N, Negoro S. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997;75:306309.

    • Search Google Scholar
    • Export Citation
  • 82

    Murray N, Livingston RB, Shepherd FA. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17:23002308.

    • Search Google Scholar
    • Export Citation
  • 83

    Teicher BA. Preclinical models for high-dose therapy. In: Armitage JO, Antman KH, eds. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, 2nd ed. Baltimore, MD: Williams and Wilkins; 1995:1442.

    • Search Google Scholar
    • Export Citation
  • 84

    Cohen MH, Creaven PJ, Fossieck BE Jr. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977;61:349354.

  • 85

    Johnson DH, Einhorn LH, Birch R. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987;5:17311738.

    • Search Google Scholar
    • Export Citation
  • 86

    Ihde DC, Mulshine JL, Kramer BS. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:20222034.

    • Search Google Scholar
    • Export Citation
  • 87

    Arriagada R, Le Chevalier T, Pignon JP. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:18481852.

    • Search Google Scholar
    • Export Citation
  • 88

    Thatcher N, Girling DJ, Hopwood P. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000;18:395404.

    • Search Google Scholar
    • Export Citation
  • 89

    Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991;9:499508.

    • Search Google Scholar
    • Export Citation
  • 90

    Crawford J, Ozer H, Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164170.

    • Search Google Scholar
    • Export Citation
  • 91

    Spigel DR, Townley PM, Waterhouse DM. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29:22152222.

    • Search Google Scholar
    • Export Citation
  • 92

    Spigel DR, Greco FA, Zubkus JD. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 2009;4:15551560.

    • Search Google Scholar
    • Export Citation
  • 93

    Horn L, Dahlberg SE, Sandler AB. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group study E3501. J Clin Oncol 2009;27:60066011.

    • Search Google Scholar
    • Export Citation
  • 94

    Hurria A, Kris MG. Management of lung cancer in older adults. CA Cancer J Clin 2003;53:325341.

  • 95

    Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996;348:563566.

    • Search Google Scholar
    • Export Citation
  • 96

    Souhami RL, Spiro SG, Rudd RM. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997;89:577580.

    • Search Google Scholar
    • Export Citation
  • 97

    Neubauer M, Schwartz J, Caracandas J. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with eastern cooperative oncology group performance status of 2, or age >= 70 years. J Clin Oncol 2004;22:18721877.

    • Search Google Scholar
    • Export Citation
  • 98

    Westeel V, Murray N, Gelmon K. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol 1998;16:19401947.

    • Search Google Scholar
    • Export Citation
  • 99

    Okamoto H, Watanabe K, Nishiwaki Y. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 1999;17:35403545.

    • Search Google Scholar
    • Export Citation
  • 100

    Matsui K, Masuda N, Yana T. Carboplatin calculated with Chatelut’s formula plus etoposide for elderly patients with small-cell lung cancer. Intern Med 2001;40:603606.

    • Search Google Scholar
    • Export Citation
  • 101

    Murray N, Grafton C, Shah A. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 1998;16:33233328.

    • Search Google Scholar
    • Export Citation
  • 102

    Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist 2009;14:986994.

  • 103

    Schneider BJ. Management of recurrent small cell lung cancer. J Natl Compr Canc Netw 2008;6:323331.

  • 104

    Pietanza MC, Kadota K, Huberman K. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012;18:11381145.

    • Search Google Scholar
    • Export Citation
  • 105

    Cheng S, Evans WK, Stys-Norman D, Shepherd FA. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007;2:348354.

    • Search Google Scholar
    • Export Citation
  • 106

    Ettinger DS. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol 2001;28:2729.

  • 107

    Kelly K. New chemotherapy agents for small cell lung cancer. Chest 2000;117:156S162S.

  • 108

    Masters GA, Declerck L, Blanke C. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group trial 1597. J Clin Oncol 2003;21:15501555.

    • Search Google Scholar
    • Export Citation
  • 109

    von Pawel J, Schiller JH, Shepherd FA. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658667.

    • Search Google Scholar
    • Export Citation
  • 110

    O’Brien ME, Ciuleanu TE, Tsekov H. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:54415447.

    • Search Google Scholar
    • Export Citation
  • 111

    Eckardt JR, von Pawel J, Pujol JL. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:20862092.

    • Search Google Scholar
    • Export Citation
  • 112

    Huber RM, Reck M, Gosse H. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur Respir J 2006;27:11831189.

    • Search Google Scholar
    • Export Citation
  • 113

    Shah C, Ready N, Perry M. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 2007;57:8488.

    • Search Google Scholar
    • Export Citation
  • 114

    Shipley DL, Hainsworth JD, Spigel DR. Topotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC)—a Minnie Pearl Cancer Research Network phase II trial [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 7083.

    • Search Google Scholar
    • Export Citation
  • 115

    Ettinger DS, Jotte R, Lorigan P. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:25982603.

    • Search Google Scholar
    • Export Citation
  • 116

    Inoue A, Sugawara S, Yamazaki K. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:54015406.

    • Search Google Scholar
    • Export Citation
  • 117

    Onoda S, Masuda N, Seto T. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:54485453.

    • Search Google Scholar
    • Export Citation
  • 118

    Shimokawa T, Shibuya M, Kitamura K. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. Int J Clin Oncol 2009;14:6369.

    • Search Google Scholar
    • Export Citation
  • 119

    Jotte R, Conkling P, Reynolds C. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011;29:287293.

    • Search Google Scholar
    • Export Citation
  • 120

    Bogart JA, Herndon JE II, Lyss AP. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 2004;59:460468.

    • Search Google Scholar
    • Export Citation
  • 121

    Liengswangwong V, Bonner JA, Shaw EG. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 1994;12:496502.

    • Search Google Scholar
    • Export Citation
  • 122

    Kim TH, Cho KH, Pyo HR. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 2005;235:208215.

    • Search Google Scholar
    • Export Citation
  • 123

    Rose J, Rodrigues G, Yaremko B. Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. Radiother Oncol 2009;91:282287.

    • Search Google Scholar
    • Export Citation
  • 124

    Kong FM, Ritter T, Quint DJ. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys 2011;81:14421457.

    • Search Google Scholar
    • Export Citation
  • 125

    Shirvani SM, Komaki R, Heymach JV. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012;82:e9197.

    • Search Google Scholar
    • Export Citation
  • 126

    Jeremic B, Shibamoto Y, Nikolic N. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999;17:20922099.

    • Search Google Scholar
    • Export Citation
  • 127

    Arriagada R, Le Chevalier T, Borie F. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995;87:183190.

    • Search Google Scholar
    • Export Citation
  • 128

    Auperin A, Arriagada R, Pignon JP. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476484.

    • Search Google Scholar
    • Export Citation
  • 129

    Slotman B, Faivre-Finn C, Kramer G. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664672.

  • 130

    Marsh JC, Gielda BT, Herskovic AM, Abrams RA. Cognitive sparing during the administration of whole brain radiotherapy and prophylactic cranial irradiation: current concepts and approaches. J Oncol 2010;2010:198208.

    • Search Google Scholar
    • Export Citation
  • 131

    Slotman BJ, Senan S. Radiotherapy in small-cell lung cancer: lessons learned and future directions. Int J Radiat Oncol Biol Phys 2011;79:9981003.

    • Search Google Scholar
    • Export Citation
  • 132

    Le Pechoux C, Dunant A, Senan S. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009;10:467474.

    • Search Google Scholar
    • Export Citation
  • 133

    Wolfson AH, Bae K, Komaki R. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81:7784.

    • Search Google Scholar
    • Export Citation
  • 134

    Slotman BJ, Mauer ME, Bottomley A. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms— results of an international phase III randomized controlled trial by the EORTC radiation oncology and lung cancer groups. J Clin Oncol 2009;27:7884.

    • Search Google Scholar
    • Export Citation
  • 135

    Maranzano E, Trippa F, Casale M. 8 Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. Radiother Oncol 2009;93:174179.

    • Search Google Scholar
    • Export Citation
  • 136

    Lutz S, Berk L, Chang E. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965976.

    • Search Google Scholar
    • Export Citation
  • 137

    Ferrell B, Koczywas M, Grannis F, Harrington A. Palliative care in lung cancer. Surg Clin North Am 2011;91:403417.

  • 138

    Tsao MN, Lloyd N, Wong RK. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012;4:CD003869.

    • Search Google Scholar
    • Export Citation
  • 139

    Johnson BE, Linnoila RI, Williams JP. Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. J Clin Oncol 1995;13:101111.

    • Search Google Scholar
    • Export Citation
  • 140

    Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998;90:13351345.

  • 141

    Richardson GE, Tucker MA, Venzon DJ. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993;119:383390.

    • Search Google Scholar
    • Export Citation
  • 142

    Kawahara M, Ushijima S, Kamimori T. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br J Cancer 1998;78:409412.

    • Search Google Scholar
    • Export Citation
  • 143

    Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340:b5569.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1071 779 109
PDF Downloads 199 168 21
EPUB Downloads 0 0 0